Question: Problem: Article: Morgan, 24, scored two tries as the Blues reached the European Challenge Cup quarter-finals with a 37-21 win.
"You need to be able to put pressure on kickers to force loose kicks but that's why we've got him here," Wilson said.
"He's electric when he's got that type of opportunity and I thought he was fantastic in that second half."
The Blues will face Gloucester at Kingsholm in the quarter-finals, after Stade Francais beat Harlequins 27-17 in their final group game.
They could have faced a last eight tie against fellow Welsh region Ospreys if Quins had beaten the French side on Sunday.
Wilson continued: "If you kick loosely to him [Morgan], his instinct and where to come back was superb. We saw that today and that's why we've got him out there."
Former Bristol back Morgan set up Sam Warburton to run in late on in their win against Bristol and says they need to maintain the rapport in their back line.
"We've got a good back three at the Blues. We are all on the same page to counter-attack, which is paying off," Morgan told BBC Radio Wales.
"We need to keep that up for the rest of the season. With the season we've had, it's good [to reach the quarter-finals]. We've had a couple of wins and losses but to get through is pretty special. Now we need to kick on.
"Whoever we get, it's going to be a tough game, but I think if we play the best rugby we can, we can give anyone a game."
Blues' quarter final opponents will be decided by the outcome of the Stade Francais v Harlequins match at 13:00 GMT on Sunday.
A Harlequins win would see Blues face Welsh rivals Ospreys at the Liberty Stadium while a home win would mean Danny Wilson's side facing Gloucester away.
Answer: [[Cardiff Blues head coach Danny Wilson says Matthew Morgan's second-half performance against Bristol proved decisive in their victory.]]

Problem: Article: The 21-year-old, who will command a development fee, becomes the Ibrox side's ninth signing of the summer.
The winger scored four times in the English League Cup last season.
"I am very excited, there are great facilities, the lads are great, the manager is great, the staff are great so I just can't wait to get started," Dodoo told the Rangers website.
"I sense a similar spirit to Leicester last season here, the lads were together and here it is exactly the same, the lads are just really good friends.
"That's got Leicester to where they were because they were a really tight group and I see the same thing here."
Rangers manager Mark Warburton, speaking after Tuesday's 2-0 League Cup win over Annan, said: "Joe is like Jordan Rossiter. He's young with great potential - an exciting talent, technically very strong, a good athlete and a good size.
"He will come in and be keen to make an impression and we're delighted to get him."
Dodoo follows Joey Barton, Matt Crooks, Matt Gilks, Clint Hill, Lee Hodson, Niko Kranjcar, Jordan Rossiter and Josh Windass in moving to Ibrox this summer.
Warburton also revealed that right-back James Tavernier is close to signing a new deal, with discussions continuing with striker Martyn Waghorn.
"To get Wes Foderingham and Rob Kiernan to extend their deals by a year is good news," said Warburton.
"Tav is all agreed too, it's an extra year as well. The paperwork will be done in the next couple of days.
"The discussions with Waghorn go on. I know you guys make a big deal out of it but these discussions go on. But Waggy's attitude has been first class."
Answer: [[Forward Joe Dodoo has signed a four-year contract with Rangers after leaving Leicester City.]]

Problem: Article: The study, published in the journal Cell, shows that nearly nine in 10 men had gene mutations that could be targeted with drugs.
The study was led in the UK by scientists at the Institute of Cancer Research (ICR) London in collaboration with several teams in the United States.
Researchers analysed the genetic codes of tumours from 150 patients with metastatic - or advanced - prostate cancer, whose disease had spread to other parts of the body.
They found that 89% had genetic aberrations for which there were existing drugs or treatments undergoing clinical trials.
Prof Johann de Bono, of the ICR and Royal Marsden NHS Foundation Trust told the BBC:  "This is truly a game-changer.  We are calling this prostate cancer's Rosetta Stone, because we can now decode the disease for the first time.
"In the past, we used to treat lethal prostate cancer as a single illness but this shows that it is a group of diseases, each driven by their own set of mutations."
Prof de Bono said it meant that, using genetic testing, it would be possible to individualise patient care, heralding the arrival of personalised treatment for advanced prostate cancer.
More than 40,000 men are diagnosed with prostate cancer and nearly 11,000 die in the UK each year.
Nearly all men with advanced disease develop resistance to hormone therapy, which is used to prevent prostate cancer cells from growing.
In the study, nearly two-thirds of the patients had mutations in a molecule that interacts with the male hormone androgen, which is targeted in current treatments.
Scientists at the ICR believe this could open up new avenues for hormone therapy.
Mutations in BRCA1 and BRCA2 genes were found in nearly one in five patients.
Trials at the Royal Marsden/ICR have already shown prostate cancer patients with BRCA mutations can benefit from drugs called Parp inhibitors which disrupt cancer cells' DNA repair mechanism.
One of these drugs, called olaparib, is now licensed by the EU to treat women with ovarian cancer, who carry BRCA mutations.
The research is part of a move towards treating cancer - not just by its site of origin - such as breast, lung or prostate - but with medicines which target the individual genetic mutations driving the disease which can be common across several cancers.
Prof Paul Workman, ICR chief executive said: "This major new study opens up the black box of metastatic cancer, and has found inside a wealth of genetic information that I believe will change the way we think about and treat advanced disease."
Dr Iain Frame, director of research at Prostate Cancer UK said: "This is incredibly exciting and ground-breaking research. It suggests for the first time the list of genetic mutations to search for in order to build up a blueprint of a man's prostate cancer once it has spread.
"This could provide the information about the best routes of attack in each individual case which is crucial if we are to reduce the number of men dying needlessly from this disease."
Answer:
Answer: [[Scientists have unveiled a comprehensive genetic map of advanced prostate cancer, hailing it as the disease's "Rosetta Stone".]]